Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage. [electronic resource]
Producer: 19990326Description: 697-9 p. digitalISSN:- 0031-6970
- Arteriosclerosis -- genetics
- Clofibric Acid -- analogs & derivatives
- DNA Damage
- Female
- Fibric Acids
- Humans
- Hypolipidemic Agents -- therapeutic use
- Kinetics
- Lipoproteins -- genetics
- Lipoproteins, HDL -- blood
- Lipoproteins, LDL -- blood
- Lymphocytes -- drug effects
- Male
- Middle Aged
- Oxidation-Reduction
- Phenotype
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.